Private equity firms play ‘pass the Parexel’ with $8.5bn handover deal
pharmaphorum
JULY 5, 2021
Four years after being taken private, Parexel has been sold again, with Goldman Sachs’ private equity arm and EQT paying $8.5 The new deal will assists the company’s focus “on advancing and innovating Parexel to meet our customers’ needs across the evolving clinical development landscape,” he added.
Let's personalize your content